CN Patent

CN110505882A — 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法

Assigned to Merck Sharp and Dohme BV · Expires 2019-11-26 · 6y expired

What this patent protects

本发明涉及用于治疗癌症的方法，其包括施用PD‑1的拮抗剂，例如抗PD‑1抗体或其抗原结合片段，和抗CTLA4抗体或其抗原结合片段，其中CTLA4抗体或其抗原结合片段以固定剂量给予。还提供了包含抗PD‑1抗体的剂量和抗CTLA4抗体的剂量的组合物和试剂盒，及其用途。

USPTO Abstract

本发明涉及用于治疗癌症的方法，其包括施用PD‑1的拮抗剂，例如抗PD‑1抗体或其抗原结合片段，和抗CTLA4抗体或其抗原结合片段，其中CTLA4抗体或其抗原结合片段以固定剂量给予。还提供了包含抗PD‑1抗体的剂量和抗CTLA4抗体的剂量的组合物和试剂盒，及其用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110505882A
Jurisdiction
CN
Classification
—
Expires
2019-11-26
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.